Beyond Boundaries in ERBB2-Positive Brain Metastatic Breast Cancer
Menée à partir de données portant sur 272 patientes et 2 patients atteints d'un cancer du sein ERBB2+ et présentant des métastases au moins au niveau du système nerveux central (âge médian : 53,7 ans ; durée médiane de suivi : 3,7 ans), cette étude estime la survie globale en fonction de la localisation des métastases ainsi que la mortalité liée aux métastases cérébrales
The study by Ferraro et al of a retrospective cohort from the Memorial Sloan Kettering Cancer Center (MSK) fundamentally shifted how we should interpret central nervous system (CNS) involvement in patients with ERBB2-positive (ERBB2+) metastatic breast cancer. No longer just an inexorable harbinger of decline, instead metastatic breast cancer with CNS involvement is reframed by this research as a dynamic landscape imbued with therapeutic potential—a locus of opportunities. Far from being yet another contribution to the already monumental canon of oncology literature, the study by Ferraro et al constitutes a critical inflection point that demands that we recalibrate both our clinical expectations and our ambitions not merely as an addition but as a benchmark to shape the future.
JAMA Network Open 2024